Point72 Asset Management
TRDA icon

Point72 Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Point72 Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,871
Closed -$225K – 4510
2025
Q4 		$225K Buy
+21,871
New +$184K ﹤0.01% 3594
2023
Q2 		– Sell
-2,840
Closed -$41.2K – 2785
2023
Q1 		$41.2K Buy
+2,840
New +$37.9K ﹤0.01% 1821

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's TRDA Position: Q1 2026 in Review

Point72 Asset Management sold out of Entrada Therapeutics (TRDA) in Q1 2026, closing a stake of 21,871 shares — an estimated $225K sold.

Point72 Asset Management first reported a position in TRDA in Q1 2023 and held it in 2 quarters. The position peaked at $225K in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Point72 Asset Management reported no remaining Entrada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 21,871 Entrada Therapeutics shares in Q1 2026, an estimated $225K.
  • Point72 Asset Management first reported a position in Entrada Therapeutics in Q1 2023 and held it in 2 quarters.
  • Point72 Asset Management's Entrada Therapeutics position peaked at $225K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.